The Centre for Digestive Diseases is a busy clinical practice which deals predominantly with gastrointestinal disorders, with a leaning towards research into Irritable Bowel Syndrome and Inflammatory Bowel Disease. With a background of research work in neurotransmitters and motility with postgraduate work at the Mayo Clinic in these topics under Professor Sid Philips, Borody's research interests have evolved from ms towards mD.
He is actively involved in a prospective trial of Crohn's therapy
using antimicrobial agents against MAP and has been instrumental in setting up the large Australian multi-centre trial designed to treat severe Crohn's disease, using clarithromycin, rifabutin, and clofazimine.
Dr. Borody has pioneered a technique of repopulating the gut with beneficial bacteria, using fecal material from healthy individuals introduced into the bowel of a patient deficient in beneficial bacteria. Absence of such bacteria allows harmful bacteria to thrive, releasing toxins and causing a variety of intestinal disorders.